Volta Medical Artificial Intelligence-guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation
AI-Guided Cardiac Ablation in combination with pulmonary vein isolation was superior to the standard of care in the treatment of Persistent Atrial Fibrillation
Volta Medical Announces Publication of Landmark Clinical Trial in Nature Medicine. This trial marks the first large-scale demonstration of the benefits of AI in interventional cardiology.
MARSEILLE, France, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, today announced the publication of the landmark TAILORED-AF clinical trial in Nature Medicine, which demonstrated that an AI-guided procedure for persistent atrial fibrillation (AF) in combination with conventional pulmonary vein isolation (PVI) treatment, resulted in better outcomes than PVI alone. In particular, the study showed superiority in the percentage of patients that achieved freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. Despite advances in catheter ablation technology, persistent AF remains one of the most challenging subtypes of atrial fibrillation to treat, affecting over 70% of all patients with atrial fibrillation globally.i
The TAILORED-AF clinical trial is the first large-scale transatlantic randomized controlled trial (RCT) of ablation in a persistent atrial fibrillation (AF) population to show the benefit of going beyond conventional pulmonary vein isolation (PVI)-only extra-pulmonary vein procedure. Previous studies looking at ablation strategies for persistent AF patients have not demonstrated superior efficacy to PVI alone. The Volta AF-Xplorer™ is a digital AI companion designed to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs) known as spatio-temporal dispersed EGMs, this technology was used in the TAILORED-AF trial.
'Previously, there has not been a replicable, effective treatment strategy for patients with persistent atrial fibrillation. Volta's AI solution finally offers a solution for this large and underserved patient population,' said Théophile Mohr-Durdez, CEO and co-founder of Volta Medical. 'The TAILORED-AF trial, highlights AI's ability to help physicians treat cardiovascular disease and improve patient outcomes. In fact, this is the first large-scale international RCT in interventional cardiology demonstrating superior efficacy through the use of AI.'
Summary and Results: Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation (TAILORED-AF) Study
In the clinical trial, adults with symptomatic persistent or long-standing persistent AF who were candidates for a first-time ablation were enrolled in Europe and the United States. A total of 187 patients underwent a tailored cardiac ablation guided by Volta's AI in addition to PVI (Tailored cohort), and 183 patients received the conventional treatment of PVI-only (Anatomical cohort) and all were followed up for 12 months. A total of 51 electrophysiologists at 26 centers in 5 countries across the US and the EU participated. For access to the full publication visit https://www.nature.com/articles/s41591-025-03517-w.
The trial met the primary endpoint by demonstrating superior results in patients assigned to the Tailored cohort compared to the Anatomical cohort.
88% of patients in the Tailored cohort experienced freedom from AF 12 months after one procedure with or without anti-arrhythmic drugs compared to 70% in the Anatomical cohort (log rank p < 0.0001).
In the Tailored cohort, patients experienced a higher rate of freedom from any arrhythmia after 1.2 procedures than in the Anatomical cohort (79% vs. 71%, log rank p < 0.01). Recurrences in the Tailored cohort were regarded as a 'simplification' of AF which are generally easier to ablate and can be seen as a step towards stable sinus rhythm.
The trial also examined several pre-specified secondary endpoints and a pre-specified subgroup analysis of patients with sustained persistent AF lasting 6 months or longer prior to enrollment. These patients represent a more advanced AF disease progression. Patients in the Tailored cohort experienced a significantly higher rate of freedom from any arrhythmia after one single procedure than in the Anatomical cohort (62% vs. 48%, log rank p = 0.04).
The safety endpoint did not differ between the groups, although the procedure and ablation time were twice as long in the Tailored arm, consistent with treatment time for other PVI+ methods.
'Atrial fibrillation, when left untreated, doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke. However, advancements in AI are transforming this landscape,' said Seth Goldbarg, MD, FACC, FHRS, Cardiologist, NewYork-Presbyterian, Queens. 'This trial featuring AI-guided assessment of AF represents a true milestone for improvement of outcomes for this underserved and difficult to treat patient community.'
About Atrial Fibrillation
The American Heart Association defines AF as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart-related complications.ii Approximately 33 million patients worldwide are living with AF.iii,iv Even though untreated AF doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition. It is estimated that only 15% of the eligible 2.5 million US patients with AF are currently being treated with catheter ablation.v
About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions with the aim of assisting cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, France, the company's mission is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data. The Volta AF-Xplorer™ is a digital AI companion designed to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs) known as spatio-temporal dispersed EGMs during AF and atrial tachycardia procedures. The AF-Xplorer™ has been engineered for versatility and its use has been demonstrated with the most popular AF mapping and recording systems, as well as with the most common ablation modalities. The solution is U.S. FDA 510(k) cleared and European CE Mark approved. For more information, visit the company's website at www.volta-medical.com. Volta Medical has created a therapy awareness program AI for Persistent AF Care designed to educate the underserved AF patient community, for more information, visit www.aiforafib.com.
U.S. Media ContactGlenn SilverFinn Partnersglenn.silver@finnpartners.comVolta ContactJeff Martin, SVP of Global MarketingVolta Medical jeffrey.martin@volta-medical.com
References
David DeLurgio, Jaswinder Gill, Syed Ahsan, Riyaz Kaba, Kristen M Plasseraud, Michael E Halkos, Hybrid Convergent Procedure for the Treatment of Persistent and Long-standing Persistent Atrial Fibrillation, Arrhythmia & Electrophysiology Review 2021;10(3):198–204. https://doi.org/10.15420/aer.2021.24
https://www.heart.org/en/health-topics/atrial-fibrillation [last accessed June 9, 2023]
Colilla S, Crow A, Petku W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112:1142–1147. DOI: 10.1016/j.amjcard.2013.05.063
https://kompetenznetz-vorhofflimmern.de/en [last accessed June 9, 2023]
https://www.mddionline.com/cardiovascular/medtronic-makes-a-double-play-for-atrial-fibrillationSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
New Continuing Education Tool from NCCN Enables Care Providers to Earn Credits While Supporting Cancer Patients
The NCCN Guidelines in Practice™ helps busy health care professionals earn credits toward maintaining licensure and board certification while applying immediate, evidence-based updates to their practice. PLYMOUTH MEETING, Pa., June 16, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has launched a new continuing education (CE) resource: NCCN Guidelines in Practice™. This new subscription service equips health professionals with continuing education tools to support care decision-making and delivery according to the latest evidence-based, expert consensus-driven recommendations, while earning continuing education and Maintenance of Certification (MOC) credits for the NCCN Guidelines engagement they are already doing during their daily clinical work. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are the recognized standard for clinical direction and policy in cancer care in the United States. They are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The 88 different NCCN Guidelines® cover treatment for nearly every type of cancer, plus prevention, screening, supportive care, and related topics. Numerous independent studies have shown that guideline-concordant care is correlated with better outcomes, longer survival, and lower costs. Individuals who subscribe to the NCCN Guidelines in Practice™ will be able to track every time they utilize one of the NCCN Guidelines while determining the best course of action for their patients—an activity that occurred more than 16 million times in 2024—and seamlessly receive continuing education credit toward maintaining their licensure and board certification. NCCN Guidelines in Practice is approved for AMA PRA Category 1 Credit™ for physicians and awards contact hours for physician associates, nurse practitioners, and nurses. Other members of the oncology care team can receive a certificate of participation. "As a board-certified, practicing oncologist myself, it's hard to express just how exciting this is," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The NCCN Guidelines in Practice put education where we need it most—at the point-of-care. This will help busy clinicians stay current on cutting-edge cancer care, particularly for some of the rarer cancer types that are covered by the NCCN Guidelines but less likely to be addressed by an in-person or online course. What's more, learning and credit for this continuing education exercise is immediate. As soon as a guideline update is published, people can earn continuing education credit for accessing the latest information." For those who prefer more in-depth explanations for updated treatment recommendations, plus a look at the underlying research and the opportunity to ask questions directly to the experts—NCCN hosts an Annual Conference, Annual Hematologic Malignancies Congress, Breast Cancer Congress, and other events and webinars. These events include in-person networking opportunities, along with virtual and on-demand access to CE content as well. "We recognize that there are providers who specialize in other areas of medicine who use the NCCN Guidelines to learn about oncology updates as well, such as primary care physicians or pediatricians," said Kristin Kline Hasson, Senior Director of Continuing Education, NCCN. "The NCCN Guidelines in Practice makes it easy for everyone to access the information they need while maintaining their required certifications, without adding to an already heavy workload." NCCN Guidelines in Practice is designed for simplicity and ease-of-use, built right into the NCCN website with no separate log-ins. The subscription service seamlessly tracks guideline usage, provides certificates of completion, and, in many cases, automatically syncs with the relevant state medical and certification boards. Visit for more information, including a list of frequently asked questions, and to purchase a subscription. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact: Rachel Darwin267-622-6624darwin@ View original content to download multimedia: SOURCE National Comprehensive Cancer Network Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Trusted Oncology Guidelines Get a Digital Makeover: National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. PLYMOUTH MEETING, Pa., June 24, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision making and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. They assist in the decision-making process of individuals involved in cancer care and prevention—including physicians, nurses, pharmacists, payers, patients and their caregivers—with the ultimate goal of improving patient care and outcomes. The new NCCN Guidelines Navigator™ presents the evidence-based, expert consensus-driven recommendations from the NCCN Guidelines in a virtual platform that allows users to search and navigate more easily. Access to the NCCN Guidelines Navigator™ is available with a free NCCN account for non-commercial use. Features of the NCCN Guidelines Navigator™ include: Seamless movement throughout a guideline using table of contents or search features Advanced search capabilities and the ability to use filters Highlighter feature for relevant content pathways Color-coded navigation links Easily viewed footnotes linked directly from the pathways Direct links to NCCN Guidelines for Patients® Direct links to the relevant NCCN Chemotherapy Order Templates (NCCN Templates®) for subscribers Zoom capabilities Mobile friendly Built-in tutorial and frequently asked questions Links to PDF format of the guideline "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Cancer prevention, screening, treatment, and supportive care that follows internationally-trusted guidelines has been shown time and again to improve outcomes for people with cancer. I'm proud that we've achieved our ambitious goal for increasing the accessibility and usability of the content from the NCCN Guidelines without compromising any quality." The NCCN Guidelines Navigator™ recently began beta testing for colon and prostate cancers. That was followed by rectal cancer, which was published on June 16, 2025. NCCN will continue to publish NCCN Guidelines Navigator™ for additional cancer types until all 88 NCCN Guidelines are available in the new format. The original pdf format will also remain available for all NCCN Guidelines. Both forms will feature the most up-to-date information users rely upon for daily use in cancer care and prevention. People who access the NCCN Guidelines in any format, including via the NCCN Guidelines Navigator™, can earn CE/MOC credit through the new NCCN Guidelines in Practice™—which was just announced earlier this month. NCCN also plans to continue to optimize this new tool, including adding artificial intelligence (AI) capabilities to make searching even more conversational and intuitive, plus increased integration with NCCN's other resource offerings. "It has been 30 years since we first launched the NCCN Guidelines; since then, they have come to be used by millions of people worldwide every year, including more than 90% of U.S. and global physicians surveyed," said Dr. Denlinger. "Cancer care is becoming increasingly effective but also more complicated every year. The new NCCN Guidelines Navigator tool simplifies the evolving evidence from the latest research, leverages expertise to put it into context, and places it at the point-of-care for decision-making support and education. This new resource integrates everything we do to support people with cancer and their care providers by defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives." Visit for more information. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact:Rachel Darwin267-622-6624darwin@ View original content: SOURCE National Comprehensive Cancer Network Sign in to access your portfolio
Business Wire
15 minutes ago
- Business Wire
Dxcover Launches US Operations to Commercialize Its AI-Powered Multiomic Cancer Detection Test
NASHVILLE, Tenn.--(BUSINESS WIRE)--Dxcover, a UK-based company improving early cancer detection with its AI-powered multiomic technology, announced today the launch of its United States headquarters in Nashville, Tennessee. The move reflects Dxcover's commitment to commercializing its PANAROMIC™ cancer test in the world's biggest life sciences market. "The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere." Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover Share Dxcover's innovative Drop. Dry. Detect. ™ approach offers a cost-effective, high-throughput, non-invasive cancer screening platform. The new facilities will allow the company to forge partnerships with local biotech and healthcare organizations, advance local manufacturing of its innovative infrared spectroscopy platform and serve as a research and development hub aimed at extending Dxcover's leadership in cancer diagnostics innovation. Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover said: "The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere. 'Nashville is well known for its dynamic business environment in the healthcare field and we look forward to collaborating with research institutes, health organizations, and biotech start-ups to promote precision medicine and enhance early cancer detection solution access. Organizations such as Life Science Tennessee and BioTN are vital to the enhancement of life sciences innovation, and Dxcover is eager to be an active member of this growing collective.' Dxcover's PANAROMIC™ technology is transforming cancer screening through a multiomic approach through infrared spectroscopy and AI-driven spectral analysis. Unlike genetic-marker-based tests, Dxcover's platform captures the complete biological signature from a tiny blood sample, enabling earlier diagnosis and better patient outcomes. The technology is scalable and already demonstrated proof-of-concept in various forms of cancer, including brain, colorectal, lung, and pancreatic cancers. Dxcover aims to bring high-tech diagnostics to underserved populations, enhancing global healthcare equity. About Dxcover Limited Dxcover's proprietary PANAROMIC™ Platform shines light on the difficulty of early cancer diagnosis. By utilizing a multiomic spectral analysis (MOSA-Dx™) approach to detect cancer, the platform can detect the presence of disease with minute volumes of liquid sample, with a turnaround time of one day. This technology goes beyond other liquid biopsy methods by harnessing the power of AI to capture the promise of the multiome, allowing early-stage detection of a range of solid tumors. Dxcover's unique AI algorithms are built on data; over 9000 patients and 250,000 spectra ensure robust diagnostic performance that can be tuned for high sensitivity or specificity. The test result is designed to be a valuable tool for clinicians to make rapid and appropriate patient management decisions. Dxcover's proprietary technology is patented globally. Dxcover's HQ is in Glasgow, UK, with their USA HQ located in Nashville, Tennessee. Dxcover's vision is to be the world leader in liquid biopsy and artificial intelligence in the early detection of cancer for better survival and quality of life. The mission is to deploy the Dxcover Platform for the triage of high-mortality and hard to diagnose cancers in high-risk populations, enabling access to value-based cancer care. For further information
